StockWatch
·
Biotechnology: Pharmaceutical Preparations
AGM/EGMApr 28, 2026, 04:10 PM

BBOT 2026 Annual Meeting Set; Michelle Doig Not Re-elected; Board Size Reduced

AI Summary

BridgeBio Oncology Therapeutics, Inc. (BBOT) announced its 2026 Annual Meeting of Stockholders will be held virtually on June 16, 2026. Stockholders will vote on the election of two Class I directors and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2026. Michelle Doig will not stand for re-election, and the board size will be reduced from nine to eight directors.

Key Highlights

  • 2026 Annual Meeting of Stockholders to be held virtually on June 16, 2026, at 1:00 p.m. Pacific Daylight Time.
  • Record date for voting at the Annual Meeting is April 20, 2026.
  • Frank McCormick and Peter Lebowitz nominated for election as Class I directors.
  • Michelle Doig will not stand for re-election to the board of directors.
  • Board of directors size to be reduced from nine to eight members.
  • Appointment of Deloitte & Touche LLP as independent auditor for 2026 to be ratified.
  • Pedro J. Beltran appointed as Class III director, replacing Eli Wallace.
  • Company is an “emerging growth company” and “smaller reporting company.”